Search Results 601-610 of 18333 for alopecia

1. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

   Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade ≤ 1 (according to the NCI CTCAE, v4.0) prior to Day 1 ...

2. A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Mayo Clinic

   Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia). Participants with ≥grade 2 pneumonitis from prior ...

3. MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer - Mayo Clinic

   Failure to recover to ≤Grade 1 from acute, reversible effects of prior chemotherapy, excluding alopecia regardless of interval since last treatment. NOTE ...

4. Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction - Mayo Clinic

   ... alopecia; Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral ...

5. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma - Mayo Clinic

   0) Grade -study baseline (except alopecia or neuropathy); Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST ...

6. Efficacy Of Daromun Neoadjuvant Intratumoral Treatment In Clinical Stage IIIB/C Melanoma Patients

   All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...

7. A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) - Mayo Clinic

   Ongoing toxicity of ≥ Grade 2 from prior anticancer therapy (except for alopecia, absolute neutrophil count [ANC] and platelets). For ANC and platelets ...

8. A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer - Mayo Clinic

   Grade > 1 alopecia or fatigue is permitted. Participants must allow a ... alopecia) not requiring systemic treatment, or conditions not expected to ...

9. Albinism - Symptoms and causes - Mayo Clinic

   In this group of inherited disorders, the body makes little or no melanin, a pigment that determines hair, skin and eye color and vision development.

10. Safety Study of SEA-CD40 in Cancer Patients - Mayo Clinic

    Recovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy (excluding alopecia) prior to initiation of study drug ...